JPRN-jRCTs031180117已完成未知
The effects of Tofogliflozin (SGLT2 inhibitor) on endogenous glucose production and insulin clearance, single and chronic effect.
Tamura Yoshifumi0 个研究点目标入组 12 人开始时间: 2019年2月13日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
1.Effect of a single dose of tofogliflozin on endogenous gluconeogenesis The decrease in PG levels induced by SGLT2i administration is required for the increase in EGP and decrease in insulin secretion. 2.Effect of tofogliflozin administration for 8 weeks on insulin clearance The insulin clearance was not altered after a single and 8-weeks administration of tofogliflozin.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 <= 65age old（—）
- 性别
- Male
入选标准
- •Type 2 diabetes mellitus men
- •-BMI range 18.5 - 30 kg/m2
- •-HbA1c range 6.5 - 10.0%
- •-The patient who did not being changed the way to take diabetes medicines(additional dosage, discontinulation of administration or changing dosage) within 12 weeks before agreement acquisition
- •-Persons who gained document consent by the patient's free intention after having sufficient explanation for participation in this study and having sufficient understanding
排除标准
- •-Type 1 diabetes mellitus
- •-Past history of taking Tofogliflozin
- •-BMI range:>30 or <18.5 kg/m2
- •-Liver dysfunction (AST, ALT => 51U/L,gamma-GTP over 101U/L)
- •-Renal dysfunction or eGFR level =< 60mL/min/1.73m2
- •-Patient with severe heart diseases (for example, heart failure and unstable angina) or the patient who occured myocardial infarction and anginal attack after 24 weeks ago from observation period
- •-Patient who had an apoplexy spasm (cerebral infarction and cerebral hemorrhage) within 24 weeks until agreement acquisition
- •-Patient with malignant tumor
- •-Patient with advanced diabetes complications (neuropathy , retinopathy and nephropathy)
- •-Patient of serious illness ketotic, a diabetic coma or the previous coma
- •-Patient with the endocrine diseases for which treatment is insufficient for hormone replenishment method of treatment (for example,pituitary disease, thyroid disease and adrenal disease)
- •-Anemia beyond the degree of middle class (hemoglobin < 9.5g/dL)
- •-Drunkard(for example 1 daily mean sake, by 3 gou and beer, more than 3 flagons)
- •-Subjects judged unsuitable to the study from staff
研究者
相似试验
已完成
不适用
Study of the effect of tofogliflozin on glucose and lipid metabolism abnormality after the test meal loading.JPRN-UMIN000015778Kanazawa Medical University10
招募中
不适用
The effect of SGLT2 inhibitor tofogliflozin on glycemic daily variation by blood glucose using CGMs in patient with type 2 diabetes.JPRN-UMIN000025454Dokkyo Medical University Department of Endocrinology and Metabolism20
已完成
2 期
Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).End Stage Renal DiseaseNCT03713190University of Pisa25
已完成
不适用
The Effect of SGLT2 inhibitor Tofogliflozin to Quality of Life of Patients with Type 2 Diabetes Mellitus ResearchType 2 diabetes mellitusJPRN-UMIN000031867HO Kyoto Medical Center, Diabetes Center30
尚未招募
不适用
Effect of tofogliflozin on glycemic fluctuation in patients with type 2 diabetes with non-alcoholic fatty liver disease (NAFLD)type 2 diabetesJPRN-UMIN000048523Minami Osaka Hospital24